Skip to content
Screener

Agios Pharmaceuticals AGIO Q2 2026 earnings

Reported July 30, 2026 · Before market open

Revenue$44.7MBeat by $18.3M
EPS-$1.69Miss by $0.04
Revenue estimate$26.4M
EPS estimate-$1.65
“We are encouraged by the ongoing U.S. commercial launch of AQVESME in thalassemia, which continues to see robust engagement from both physicians and patients. We also progressed mitapivat toward a potential new indication in sickle cell disease, highlighted by the FDA granting Priority Review for our sNDA. Beyond these milestones, we strengthened our hematology pipeline with the licensing of cevidoplenib and advancement of AG-236 into Phase 2/3 development, while maintaining disciplined capital allocation. Together, these achievements underscore our ability to deliver meaningful innovation for patients and long-term shareholder value.”
Brian Goff

Next report

Oct 29, 2026 (in a month)
Revenue estimate$53.8M
EPS estimate-$1.21

Financials

Q2 2026

Income statement

See full
Revenue$44.7M+259%
Gross profit$41.7M+288%
Operating income-$110.6M+13.0%
Net income-$100.7M+10.1%
EPS (diluted)-$1.69+12.4%

Balance sheet

See full
Cash & equivalents$99.6M+23.2%
Total debt$31.2M-36.1%
Total equity$1.0B-25.1%
Total assets$1.1B-24.7%

Cash flow

See full
Operating cash flow-$57.3M+25.7%
CapEx$1.2M+38.5%
Free cash flow-$58.5M+25.0%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.96B-7.0%
Enterprise value$1.89B-8.9%
P/S19.9×-31.6×

Profitability

See full
Gross margin92%+3.8pp
Operating margin-466.8%-173pp
Net margin-418.2%—
FCF margin-371.4%-143pp

Returns & leverage

See full
Return on equity-34.3%—
Debt / equity0×0.0×
Current ratio10.2×-4.3×

FAQ

When did Agios Pharmaceuticals report Q2 2026 earnings?
Agios Pharmaceuticals (AGIO) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Agios Pharmaceuticals's Q2 2026 revenue and EPS?
Agios Pharmaceuticals reported revenue of $44.7M and eps of $-1.69 for Q2 2026.
Did Agios Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $26.4M by $18.3M. EPS missed the consensus estimate of $-1.65 by $0.04.
How did Agios Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 259.3% from $12.5M a year earlier and eps grew 12.4% from $-1.93.
Where can I find Agios Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001439222-26-000115) and the 10-Q periodic report (0001439222-26-000118) directly on SEC EDGAR. The filing index links above go to sec.gov.